Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition

Expert Opinion on Drug Discovery

Volumn 3, Issue 12, 2008, Pages 1427-1449

  Backes, Alexander C ^a   Zech, B ^b   Felber, B ^c   Klebl, B ^d   Muller G ^e  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Pieris Pharmaceuticals GmbH   (Germany)

^c Lead Discovery Center ^*  (Germany)

^d Lead Discovery Center GmbH   (Germany)

^e PROTEROS BIOSTRUCTURES GMBH   (Germany)

Author keywords

Binding mode; Inactive conformation; Kinase inhibitors; Protein kinase; Structure based drug design

Indexed keywords

3 BENZYLOXYPYRIDINE DERIVATIVE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; A 420983; A 641593; A 770041; AAL 993; ANGIOGENESIS INHIBITOR; AURORA KINASE INHIBITOR; BENZIMIDAZOLE; CHIR 265; DORAMAPIMOD; ERLOTINIB; IMATINIB; INDOLEAMIDE DERIVATIVE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MOTESANIB; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NICOTINAMIDE; NILOTINIB; NVP AEG 082; NVP AFG 210; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK INHIBITOR; PYRIDINE DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYDROPHOBICITY; INFLAMMATORY DISEASE; MOLECULAR WEIGHT; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW;

EID: 58049211592     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440802580106     Document Type: Review

References (73)

1. Levinson NM, Kuchment O, Shen K, et al. A Src-like inactive conformation in the Abl tyrosine kinase domain. PLoS Biol 2006;4(5):753-67
2. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994;372(6508):746-54
3. Capdevifle R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502
4. Zimmermann J, Buchdunger E, Mett H, et al. Potent and selective inhibitors of the Abl-ldnase: phenylaminopyrimidine (PAP) derivatives. Bioorg Med Chem Lett 1997;7(2): 187-92
5. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20(36):5054-8
6. Schindler T, Bornmann W, Pellicena P,, et al. Structural mechanism for STI-571 inhibition ofAbelson tyrosine kinase. Science 2000;289:1938-42
7. Ongusaha PP, Kim JI, Fang L, et al. p53 induction and activation of DDR1 kinase counteract p53-meidated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J 2003;22(6): 1289-301
8. Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 2006; 18:1108-16
9. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD 173955 and imatinib (STI-571). Cancer Res 2002;62(15): 4236-43
10. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279(30):31655-63
11. Regan J, Breitfelder S, Cirillo P, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 2002;45(14):2994-3008
12. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novd allosteric binding site. Nat Struct Biol 2002;9(4):268-72
13. Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Design 2002;8(25):2269-78
14. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of Sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44
15. Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAE Cell 2004; 116:855-67
16. Cowan-Jacob SW,, Fendrich G, Floersheimer A, et al. Structural biology contributions to the discovery of drugs to treat chronic mye[ogenous leukaemia. Acta Crystallogr Sect D Biol Crystallogr 2007;D63:80-93
17. Thaimattam R, Daga P,, Rajjak SA, et al. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies. Bioorg Med Chem 2004;12:6415-25
18. Gill AL, Frederickson M, Cleasby A, et aL Identification of novel p38a MAP kinase inhibitors using fragment-based lead generation. J Med Chem 2005;48(2):414-26
19. Congreve MS, Murray CW, Carr RAE, Rees DC. Fragment-based lead discovery. Annu Pep Med Chem 2007;42:431-48
20. Gadea BB, Ruderman JV. Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol Biol Cell 2005;16(3):1305-18
21. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161 (2):267-80
22. Heron NM, Anderson M, Blowers DP, et al. SAR and inhibiror complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett 2006;16:1320-3
23. AstraZeneca UK Ltd. Crystal structure of human Aurora A kinase catalytic domain complexed with ATP analog and inhibitor and applications to structure-based drug design. WO03031606; 2003
24. AstraZenecaUK Ltd. Preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease. WO00020402; 2000
25. Cumming JG, Mckenzie CL, Bowden SG, et al. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2004; 14(21):5389-94
26. Sullivan JE, Holdgate GA, Campbell D, et al. Prevention of MKK6-dependent activation by binding to p38ot MAP kinase. Biochemistry 2005;44(50):16475-90
27. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMNI07, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:127-41
28. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102(31):11011-6
29. Horio T, Hamasaki T, Inoue T, et al. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg Med Chem Lett 2007;17:2712-7
30. Abl inhibitors. Chem Biol 2006;13:779-86
31. Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002;62(15):4244-55
32. Goldberg DR, Hao MH, Qian KC, et al. Discovery and optimization of p38 inhibitors via computer-assisted drug design. J Med Chem 2007;50(17):4016-26
33. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86
34. Dumas J, Dixon JA. VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures. Exp Opin Ther Pat 2005;15(6):647-58
35. Manley PW, Bold G, Brueggen J, et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 2004;1697(1-2):17-27
36. Hasegawa M, Nishigaki N, Washio Y, et al. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem 2007;50(18):4453-70
37. Miyazaki Y, Matsunaga S, Tang J, et al. Novel 4-amino-furo [2,3-d] pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett 2005;15(9):2203-7
38. Cee VJ, Albrecht BK, Geuns-Meyer S, et al. Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. J Med Chem 2007;50:627-40
39. Hodous BL, Geuns-Meyer SD, Hughes PE, et al. Evolution of a highly selective and potent 2-(pyridin-2-yl)- 1,3,5-triazine Tie-2 kinase inhibitor. J Med Chem 2007;50:611-26
40. Amgen, Inc. USA. Preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity. US05070891; 2005
41. Weiss M, Bajpaj M, Bauer D, et al. Discovery, synthesis and optimization of a new class of potent KDR inhibitors: Naphthoylamides. AACR Annual Meeting; 2006; Washington DC, USA
42. Harris PA, Cheung M, Iii RNH, et al. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class ofVEGFR2 kinase inhibitors. J Med Chem 2005;48:1610-9
43. Vogtherr M, Saxena K, Hoelder S, et al. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew Chem Int Ed Eng12006;45:993-7
44. Potashman MH, Bready J, Coxon A, et al. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J Med Chem 2007;50(18):4351-73
45. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potendy inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66(17):8715-21
46. Dimauro EF, Newcomb J, Nunes JJ, et al. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: Synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 2006;49(19):5671-86
47. Fabian MA, Iii WHB, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechno12005;23(3):329-36
48. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-32
49. Wood ER, Truesdale AT, Mc Donald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-9
50. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277(48):46265-72
51. BasfAG. Method of identifying inhibitors of receptor tyrosine kinase Tie-2 for regulation of neovascularization. WO01072778; 2001
52. Burchat A, Borhani DW, Calderwood DJ, et al. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett 2006;16:118-22
53. Borhani DW, Calderwood DJ, Friedman MM, et al. A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett 2004;14:2613-6
54. Burchat AF, Calderwood DJ, Friedman MM, et al. Pyrazolo[3,4-d] pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Bioorg Med Chem Lett 2002;12:1687-90
55. Calderwood DJ, Johnston DN, Munschauer R, Rafferty P. Pyrrolo[2,3-d] pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorg Med Chem Lett 2002; 12:1683-6
56. Regan J, Pargellis CA, Cirillo PF, et al. The kinetics of binding to p38 MAP kinase by analogues of BIRB 796. Bioorg Med Chem Lett 2003;13:3101-4
57. Atwell S, Adams JM, Badger J, et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004;279(53):55827-32
58. Cowan-Jacob SW, Fendrich G, Manley PW, et al. The crystal structure ofa c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005;13(6):861-71
59. Kiselyov A, Balakin KV, Tkachenko SE, Savchuk NP. Recent progress in development of non-ATP competitive small-molecule inhibitors of protein kinases. Mini Rev Med Chem 2006;6:711-7
60. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005;102(6):1992-7
61. Davidson W, Frego L, Peet GW, et al. Discovery and characterization of a substrate selective p38α inhibitor. Biochemistry 2004; 43(37):11658-71
62. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11(12):1192-7
63. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat Med 1999;5(7):810-6
64. Spicer JA, Rewcastle GW, Kaufman MD, et al. 4-Anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. J Med Chem 2007;50:5090-102
65. Davies BR, Logie A, Mckay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-19
66. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2(2):95-102
67. Hantschel O, Nagar B, Guettler S, et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003;112(6):845-57
68. Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112(6):859-71
69. Lindsley CW, Zhao Z, Leister WH, et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 2005;l5:761-4
70. Zhao Z, Robinson RG, Barnett SF, et al. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett 2008;18:49-53
71. Martelli AM, Tazzari PL, Evangelisti C, et al. Targeting for phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: From bench to bedside. Curt Med Chem 2007;14:2009-23
72. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358-64
73. Angell RM, Angell TD, Bamborough P, et al. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett 2008;18:4433-7